SAN FRANCISCO, CA (PRWEB) August 26, 2013
Mytrus Inc. announced today that they have been awarded Frost & Sullivan’s prestigious clinical trials product leadership award for their pioneering electronic informed consent application, enroll™.
Frost & Sullivan, a respected global research organization that tracks more than 250,000 companies, compared Mytrus to other market competitors in a rigorous review that touched on several elements of product design, adoption, ease of use and market potential. At the end of the review, Mytrus was named winner of the North American Product Leadership Award in Clinical Trials for 2013.
“Mytrus has developed a product that makes the cumbersome, but critical process of informed consent simple and efficient for patients and offers sponsors and regulators new opportunities to collect and track important informed consent data analytics,” said Prakhar Verma, Industry Analyst at Frost & Sullivan. “Like other truly disruptive innovations, enroll™ is simple yet powerful and defines a new market for collecting clinical trial consent electronically on all research studies.”
Informed consent forms typically run 8 to 50 pages of often-complex legal and medical information. Participants frequently fail to read or understand the documents before they consent to participating in a trial. Further, there are no requirements for assessing participants’ understanding of the protocol or risks.
“Informed consent is one of the most important, but often neglected, elements of enrolling patients in clinical trials” said Mytrus CEO Anthony Costello. “We are humbled to receive this award for our work in the area of eConsent and we are encouraged to see the number of companies rushing to adopt more patient-centered tools for clinical research.”
According to ClinicalTrials.gov, there were more than 60,000 registered clinical trials ongoing in the United States last J
Copyright©2012 Vocus, Inc.
All rights reserved